cartitude-4 cilta-cel efficacy in myeloma | binod dhakal, md | asco 2023
Published 1 year ago • 315 plays • Length 6:43Download video MP4
Download video MP3
Similar videos
-
11:43
cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
-
8:16
results from cartitude-4: cilta-cel for lenalidomide-refractory multiple myeloma
-
58:19
sequencing bcma myeloma therapies
-
4:33
cilta-cel effective in lenalidomide-refractory multiple myeloma
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
2:25
cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
5:34
latest results from the cartitude-2 study testing cilta-cel in multiple myeloma patients
-
4:10
cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma
-
9:03
cartitude-1: final results of ciltacabtagene autoleucel in heavily pretreated relapsed refractory mm
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
4:21
cartitude-1: health-related qol with cilta-cel for myeloma
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
8:45
updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
-
1:38
cartitude-1 final results: pfs of cilta-cel in patients with heavily pre-treated r/r myeloma
-
2:09
cartitude-1: cilta-cel improves hrqol for patients with myeloma